The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
Conclusions:
Saxagliptin reverses PACs dysfunction associated with T2D in vitro and improves inducible angiogenesis by circulating cells in vivo. These data add knowledge to the potential pleiotropic cardiovascular effects of DPP-4 inhibition.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Nicol PoncinaMattia AlbieroLisa MenegazzoRoberta CappellariAngelo AvogaroGian Fadini Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Genetics | Heart | Men